Calliditas Common Stock Total Equity vs Total Current Liabilities Analysis

CALT Stock

USD 22.19 0.16 0.73%

Calliditas Therapeutics financial indicator trend analysis is way more than just evaluating Calliditas Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Calliditas Therapeutics is a good investment. Please check the relationship between Calliditas Therapeutics Common Stock Total Equity and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calliditas Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.

Common Stock Total Equity vs Total Current Liabilities

Common Stock Total Equity vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Calliditas Therapeutics Common Stock Total Equity account and Total Current Liabilities. At this time, the significance of the direction appears to have strong relationship.

The correlation between Calliditas Therapeutics' Common Stock Total Equity and Total Current Liabilities is 0.67. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Calliditas Therapeutics, assuming nothing else is changed. The correlation between historical values of Calliditas Therapeutics' Common Stock Total Equity and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Calliditas Therapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Common Stock Total Equity i.e., Calliditas Therapeutics' Common Stock Total Equity and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.67

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Total Current Liabilities

Total Current Liabilities is an item on Calliditas Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Calliditas Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Calliditas Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Calliditas Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calliditas Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.At this time, Calliditas Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 19.7 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (39.73) in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	7.1M	12.5M	73.2M	76.9M
Depreciation And Amortization	1K	12.9M	16.6M	17.4M

Interest Expense Depreciation And Amortization

Calliditas Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Net Tangible Assets	Current Deferred Revenue
Total Assets		0.51	0.79	0.81	0.76	-0.58	-0.88	0.92	0.98	0.89	0.59	0.98	0.78	0.97	0.83	0.91	0.47	0.99	0.75	0.75	0.99	0.99	0.82	0.68	0.7	0.43
Other Current Liab	0.51		0.86	0.19	0.83	0.2	-0.8	0.42	0.42	0.74	-0.18	0.42	0.83	0.44	0.48	0.62	1.0	0.5	0.87	0.85	0.48	0.55	0.68	0.87	0.29	-0.09
Total Current Liabilities	0.79	0.86		0.42	0.94	-0.02	-0.97	0.81	0.71	0.92	0.32	0.71	0.98	0.67	0.71	0.77	0.83	0.77	1.0	0.96	0.76	0.79	0.89	0.98	0.37	0.4
Total Stockholder Equity	0.81	0.19	0.42		0.44	-0.9	-0.56	0.61	0.89	0.64	0.52	0.89	0.43	0.85	0.58	0.85	0.17	0.83	0.36	0.42	0.84	0.8	0.54	0.25	0.93	0.18
Property Plant And Equipment Net	0.76	0.83	0.94	0.44		-0.05	-0.97	0.74	0.69	0.91	0.22	0.69	0.92	0.68	0.74	0.77	0.79	0.78	0.94	1.0	0.73	0.78	0.97	0.93	0.41	0.25
Net Debt	-0.58	0.2	-0.02	-0.9	-0.05		0.19	-0.38	-0.71	-0.28	-0.51	-0.71	-0.06	-0.68	-0.33	-0.61	0.22	-0.6	0.04	-0.02	-0.63	-0.57	-0.18	0.14	-0.85	-0.12
Retained Earnings	-0.88	-0.8	-0.97	-0.56	-0.97	0.19		-0.85	-0.81	-0.96	-0.36	-0.81	-0.95	-0.79	-0.78	-0.85	-0.76	-0.88	-0.96	-0.97	-0.85	-0.88	-0.95	-0.93	-0.49	-0.36
Accounts Payable	0.92	0.42	0.81	0.61	0.74	-0.38	-0.85		0.87	0.84	0.76	0.87	0.8	0.83	0.78	0.75	0.37	0.89	0.78	0.73	0.9	0.88	0.81	0.74	0.43	0.73
Cash	0.98	0.42	0.71	0.89	0.69	-0.71	-0.81	0.87		0.82	0.63	1.0	0.73	0.97	0.76	0.94	0.38	0.97	0.66	0.67	0.99	0.97	0.75	0.59	0.81	0.42
Non Current Assets Total	0.89	0.74	0.92	0.64	0.91	-0.28	-0.96	0.84	0.82		0.39	0.82	0.86	0.8	0.82	0.83	0.72	0.89	0.91	0.91	0.84	0.87	0.91	0.85	0.52	0.34
Non Currrent Assets Other	0.59	-0.18	0.32	0.52	0.22	-0.51	-0.36	0.76	0.63	0.39		0.63	0.35	0.51	0.5	0.4	-0.23	0.55	0.29	0.2	0.61	0.51	0.37	0.25	0.29	0.9
Cash And Short Term Investments	0.98	0.42	0.71	0.89	0.69	-0.71	-0.81	0.87	1.0	0.82	0.63		0.73	0.97	0.76	0.94	0.38	0.97	0.66	0.67	0.99	0.97	0.75	0.59	0.81	0.42
Net Receivables	0.78	0.83	0.98	0.43	0.92	-0.06	-0.95	0.8	0.73	0.86	0.35	0.73		0.68	0.67	0.8	0.78	0.76	0.98	0.94	0.78	0.79	0.88	0.97	0.42	0.42
Common Stock Total Equity	0.97	0.44	0.67	0.85	0.68	-0.68	-0.79	0.83	0.97	0.8	0.51	0.97	0.68		0.74	0.92	0.41	0.98	0.63	0.66	0.98	0.99	0.73	0.55	0.8	0.29
Common Stock Shares Outstanding	0.83	0.48	0.71	0.58	0.74	-0.33	-0.78	0.78	0.76	0.82	0.5	0.76	0.67	0.74		0.66	0.43	0.82	0.7	0.73	0.78	0.78	0.79	0.66	0.43	0.37
Capital Surpluse	0.91	0.62	0.77	0.85	0.77	-0.61	-0.85	0.75	0.94	0.83	0.4	0.94	0.8	0.92	0.66		0.58	0.92	0.73	0.76	0.94	0.94	0.78	0.66	0.87	0.21
Other Current Assets	0.47	1.0	0.83	0.17	0.79	0.22	-0.76	0.37	0.38	0.72	-0.23	0.38	0.78	0.41	0.43	0.58		0.46	0.84	0.81	0.44	0.52	0.63	0.83	0.26	-0.13
Other Stockholder Equity	0.99	0.5	0.77	0.83	0.78	-0.6	-0.88	0.89	0.97	0.89	0.55	0.97	0.76	0.98	0.82	0.92	0.46		0.73	0.76	0.98	0.99	0.84	0.66	0.73	0.38
Total Liab	0.75	0.87	1.0	0.36	0.94	0.04	-0.96	0.78	0.66	0.91	0.29	0.66	0.98	0.63	0.7	0.73	0.84	0.73		0.96	0.72	0.75	0.89	0.99	0.31	0.39
Property Plant And Equipment Gross	0.75	0.85	0.96	0.42	1.0	-0.02	-0.97	0.73	0.67	0.91	0.2	0.67	0.94	0.66	0.73	0.76	0.81	0.76	0.96		0.72	0.77	0.96	0.95	0.39	0.25
Total Current Assets	0.99	0.48	0.76	0.84	0.73	-0.63	-0.85	0.9	0.99	0.84	0.61	0.99	0.78	0.98	0.78	0.94	0.44	0.98	0.72	0.72		0.99	0.78	0.65	0.77	0.43
Common Stock	0.99	0.55	0.79	0.8	0.78	-0.57	-0.88	0.88	0.97	0.87	0.51	0.97	0.79	0.99	0.78	0.94	0.52	0.99	0.75	0.77	0.99		0.81	0.68	0.74	0.35
Property Plant Equipment	0.82	0.68	0.89	0.54	0.97	-0.18	-0.95	0.81	0.75	0.91	0.37	0.75	0.88	0.73	0.79	0.78	0.63	0.84	0.89	0.96	0.78	0.81		0.86	0.45	0.35
Short Long Term Debt Total	0.68	0.87	0.98	0.25	0.93	0.14	-0.93	0.74	0.59	0.85	0.25	0.59	0.97	0.55	0.66	0.66	0.83	0.66	0.99	0.95	0.65	0.68	0.86		0.22	0.4
Net Tangible Assets	0.7	0.29	0.37	0.93	0.41	-0.85	-0.49	0.43	0.81	0.52	0.29	0.81	0.42	0.8	0.43	0.87	0.26	0.73	0.31	0.39	0.77	0.74	0.45	0.22		-0.05
Current Deferred Revenue	0.43	-0.09	0.4	0.18	0.25	-0.12	-0.36	0.73	0.42	0.34	0.9	0.42	0.42	0.29	0.37	0.21	-0.13	0.38	0.39	0.25	0.43	0.35	0.35	0.4	-0.05

Click cells to compare fundamentals

Calliditas Therapeutics Account Relationship Matchups

Calliditas Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	845.2M	1.5B	1.5B	2.0B	1.9B	1.0B
Other Current Liab	25.6M	51.8M	13.9M	18.0M	287.9M	302.3M
Total Current Liabilities	53.4M	105.6M	135.4M	325.2M	407.1M	427.5M
Total Stockholder Equity	788.1M	1.2B	1.0B	766.3M	334.8M	582.2M
Property Plant And Equipment Net	6.1M	5.4M	39.6M	31.9M	54.2M	57.0M
Net Debt	(747.5M)	(991.5M)	(742.3M)	(520.3M)	5.4M	5.7M
Retained Earnings	(488.1M)	(918.6M)	(1.5B)	(1.8B)	(2.3B)	(2.2B)
Accounts Payable	24.4M	53.8M	68.0M	160.4M	100.6M	55.2M
Cash	753.5M	996.3M	955.5M	1.2B	973.7M	694.4M
Non Current Assets Total	24.1M	469.6M	447.1M	540.8M	625.4M	656.7M
Cash And Short Term Investments	753.5M	996.3M	955.5M	1.2B	973.7M	694.4M
Common Stock Total Equity	667K	1.4M	1.5M	2.0M	2.3M	1.2M
Common Stock Shares Outstanding	36.9M	44.9M	50.8M	53.0M	53.7M	42.4M
Liabilities And Stockholders Equity	845.2M	1.5B	1.5B	2.0B	1.9B	1.0B
Other Current Assets	1.6M	2.3M	22.8M	1K	92.8M	97.4M
Other Stockholder Equity	1.3B	2.1B	2.5B	2.6B	2.6B	1.6B
Total Liab	57.1M	250.2M	451.6M	1.2B	1.6B	1.6B
Property Plant And Equipment Gross	6.1M	5.4M	39.6M	35.6M	62.3M	65.5M
Total Current Assets	821.1M	1.0B	1.0B	1.4B	1.3B	772.7M
Accumulated Other Comprehensive Income	(45K)	(6.1M)	(27.0M)	9.3M	(5.2M)	(5.0M)
Common Stock	1.5M	2.0M	2.1M	2.4M	2.7M	1.6M
Property Plant Equipment	6.1M	5.4M	39.6M	31.9M	36.7M	38.5M
Net Tangible Assets	772.0M	749.1M	608.9M	282.4M	324.8M	479.2M
Other Assets	1.9M	600K	8.1M	(1K)	1.0	0.95
Non Current Liabilities Total	3.8M	144.5M	316.2M	861.5M	1.2B	1.2B
Net Invested Capital	788.1M	1.2B	1.2B	1.5B	1.3B	1.0B
Net Working Capital	767.8M	931.2M	877.3M	1.1B	868.0M	814.3M
Capital Stock	1.5M	2.0M	2.1M	2.4M	2.7M	2.2M

Pair Trading with Calliditas Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Calliditas Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Calliditas Therapeutics will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Calliditas Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Calliditas Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Calliditas Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Calliditas Therapeutics to buy it.

The correlation of Calliditas Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Calliditas Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Calliditas Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Calliditas Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Calliditas Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Calliditas Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Calliditas Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Calliditas Therapeutics Stock:

How To Invest In Calliditas

Details

Is Calliditas Stock a good investment?

Details

What is Calliditas Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calliditas Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.

You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Complementary Tools for Calliditas Stock analysis

When running Calliditas Therapeutics' price analysis, check to measure Calliditas Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calliditas Therapeutics is operating at the current time. Most of Calliditas Therapeutics' value examination focuses on studying past and present price action to predict the probability of Calliditas Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calliditas Therapeutics' price. Additionally, you may evaluate how the addition of Calliditas Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Bonds Directory Find actively traded corporate debentures issued by US companies
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Money Managers Screen money managers from public funds and ETFs managed around the world

Is Calliditas Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calliditas Therapeutics. If investors know Calliditas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calliditas Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.63)

Revenue Per Share

44.972

Quarterly Revenue Growth

0.052

Return On Assets

(0.13)

Return On Equity

(0.85)

The market value of Calliditas Therapeutics is measured differently than its book value, which is the value of Calliditas that is recorded on the company's balance sheet. Investors also form their own opinion of Calliditas Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calliditas Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calliditas Therapeutics' market value can be influenced by many factors that don't directly affect Calliditas Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Calliditas Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calliditas Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calliditas Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Calliditas Common Stock Total Equity vs Total Current Liabilities Analysis

Common Stock Total Equity vs Total Current Liabilities

Common Stock Total Equity vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Common Stock Total Equity

Total Current Liabilities

Calliditas Therapeutics fundamental ratios Correlations

Calliditas Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Calliditas Therapeutics fundamental ratios Accounts

Pair Trading with Calliditas Therapeutics

Complementary Tools for Calliditas Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Assets	+ 1.0	Other Current Liab
Total Liab	+ 1.0	Total Current Liabilities
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Other Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets

Property Plant And Equipment Gross	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Property Plant And Equipment Net
Retained Earnings	- 0.97	Total Current Liabilities
Total Liab	- 0.96	Retained Earnings
Non Current Assets Total	- 0.96	Retained Earnings
Property Plant Equipment	- 0.95	Retained Earnings